All In Biotech

Drug Trial Radar · NCT05701995

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Jan 31, 2023

Primary completion

Aug 23, 2024

Study completion May 29, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Conditions

  • Psoriasis

Interventions

  • DeucravacitinibDrug

    Specified dose on specified days.

  • PlaceboOther

    Specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16Time frame: At Week 16

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 0006

    Phoenix, Arizona

  • Local Institution - 0034

    Scottsdale, Arizona

  • Local Institution - 0015

    North Little Rock, Arkansas

  • Local Institution - 0004

    Bakersfield, California

  • Local Institution - 0009

    Sacramento, California

  • Local Institution - 0022

    San Diego, California

  • Local Institution - 0030

    Centennial, Colorado

  • Local Institution - 0024

    Washington D.C., District of Columbia

  • Local Institution - 0027

    Brandon, Florida

  • Local Institution - 0016

    Coral Gables, Florida

  • Riverchase Dermatology

    Pembroke Pines, Florida

  • Local Institution - 0037

    Atlanta, Georgia

  • Local Institution - 0020

    Snellville, Georgia

  • Local Institution - 0007

    Rolling Meadows, Illinois

  • Local Institution - 0025

    Skokie, Illinois

  • Local Institution - 0036

    Springfield, Illinois

  • Local Institution - 0003

    Baton Rouge, Louisiana

  • Local Institution - 0018

    Rockville, Maryland

  • Local Institution - 0010

    Auburn Hills, Michigan

  • Local Institution - 0002

    Waterford, Michigan

  • Local Institution - 0017

    Las Vegas, Nevada

  • Local Institution - 0035

    Reno, Nevada

  • Local Institution - 0032

    New York, New York

  • Local Institution - 0013

    New York, New York

  • Local Institution - 0001

    Rochester, New York

  • Local Institution - 0005

    Bexley, Ohio

  • Local Institution - 0012

    Mayfield Heights, Ohio

  • Local Institution - 0019

    Charleston, South Carolina

  • Local Institution - 0029

    Cypress, Texas

  • Local Institution - 0028

    Frisco, Texas

  • Local Institution - 0008

    South Jordan, Utah

  • Local Institution - 0033

    Springville, Utah

  • Local Institution - 0021

    Bellevue, Washington

  • Local Institution - 0031

    Mill Creek, Washington

  • Local Institution - 0014

    Spokane, Washington

  • Local Institution - 0040

    Caguas, Puerto Rico

  • Local Institution - 0038

    Carolina, Puerto Rico

  • Local Institution - 0039

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.